IR@PKUHSC  > 北京大学第一临床医学院  > 心血管内科
学科主题临床医学
Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial
Zheng, Bo1; Jiang, Jie1; Liu, Huiliang2; Zhang, Jun3; Li, Hui4; Su, Xi5; Wang, Haichang6; Song, Zhiyuan7; Han, Yaling8; Lei, Han9; Cong, Hongliang10; Zhang, Zheng11; Ma, Yitong12; Wang, Jian′ an13; Xu, Biao14; Sun, Yingxian15; Gao, Chuanyu16; Zheng, Yang17; Liu, Bin18; Huang, Dejia19; Li, Bao20; Huang, Congxin21; Yang, Tianlun22; Wan, Zheng23; Jia, Shaobin24; Chen, Dafang25; Ge, Junbo26; Huo, Yong1
关键词Atorvastatin Percutaneous coronary intervention Periprocedural myocardial infarction
刊名EUROPEAN HEART JOURNAL SUPPLEMENTS
2015-03-01
DOI10.1093/eurheartj/suv021
17期:B页:B47-B56
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]TREATMENT PLATELET REACTIVITY ; CLOPIDOGREL RESPONSIVENESS ; OUTCOMES ; GENE ; IMPLANTATION ; ASPIRIN ; EVENTS ; IMPACT
英文摘要

Although several studies have suggested that intensive statin pretreatment could reduce the incidence of procedure-related myocardial infarction in western population, the data on the effect in Asian patients have been still limited. The aim of the study was to investigate the efficacy and safety of intensive atorvastatin load in Chinese patients undergoing elective PCI. A total of 1202 patients with stable angina or non-ST-segment elevation acute coronary syndrome (NSTE-ACS) scheduled to undergo PCI received either intensive statin treatment (80 mg atorvastatin daily x 2 days before PCI and 40 mg daily x 30 days after PCI) or usual care. The primary endpoint was incidence of major adverse cardiac events (cardiac death, myocardial infarction, or unexpected target vessel revascularization) within 30 days after PCI. Safety endpoints include the incidence of contrast induced nephropathy (CIN), ALT/AST >3 upper limit of normal (ULN), CK >5 ULN. The incidence of 30-day MACE did not significantly differ between the intensive group and control group (19.4 vs 18.3%, P = 0.63). Multivariate analysis revealed age (OR = 1.024, 95% CI 1.003-1.045, P = 0.023) and total stent length as an independent predictor of 30-day MACE (OR = 1.012, 95% CI 1.007-1.018, P < 0.0001). The incidence of CIN was comparable between intensive group and control group (4.09 vs 4.39%, P = 0.795). No significant differences were observed in other safety profile at all follow-ups between treatment groups. The ISCAP trial demonstrated that serial intensive atorvastatin therapy did not improve the clinical outcome with similar safety profile comparing with usual care among Chinese patients undergoing elective PCI.

语种英语
WOS记录号WOS:000357873000004
项目编号2011BAI11B07 ; 2012ZX093016-002
资助机构National Key Technology R&amp ; D Program in the 12th Five-year Plan of China
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58543
专题北京大学第一临床医学院_心血管内科
北京大学基础医学院
作者单位1.Daqing Oilfield Gen Hosp, Dept Cardiol, Harbin, Peoples R China
2.Wuhan Asia Heart Hosp, Dept Cardiol, Wuhan, Hubei, Peoples R China
3.Tianjin Chest Hosp, Dept Cardiol, Tianjin, Peoples R China
4.Peking Univ, Hosp 1, Dept Cardiol, Beijing 100034, Peoples R China
5.Chinese Peoples Armed Police Forces, Gen Hosp, Dept Cardiol, Beijing, Peoples R China
6.HeBei Med Univ, Affiliated Hosp, Dept Cardiol, Cangzhou Cent Hosp, Cangzhou, Hebei, Peoples R China
7.Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Shanxi, Peoples R China
8.Third Mil Med Univ, Southwest Hosp, Dept Cardiol, Chongqing, Peoples R China
9.Gen Hosp Shenyang Mil Reg, Dept Cardiol, Shenyang, Liaoning, Peoples R China
10.Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China
11.Lanzhou Univ, Affiliated Hosp 1, Dept Cardiol, Lanzhou 730000, Gansu, Peoples R China
12.Xinjiang Med Univ, Affiliated Hosp 1, Dept Cardiol, Urumqi, Xinjiang, Peoples R China
13.Zhejiang Univ, Affiliated Hosp 2, Dept Cardiol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
14.Nanjing Univ, Sch Med, Dept Cardiol, Gulou Hosp, Nanjing 210008, Jiangsu, Peoples R China
15.China Med Univ, Hosp 1, Dept Cardiol, Shenyang, Liaoning, Peoples R China
16.Henan Prov Peoples Hosp, Dept Cardiol, Zhengzhou, Henan, Peoples R China
17.Jilin Univ, Hosp 1, Dept Cardiol, Changchun 130023, Jilin, Peoples R China
18.Jilin Univ, Hosp 2, Dept Cardiol, Changchun 130023, Jilin, Peoples R China
19.Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu 610064, Sichuan, Peoples R China
20.Shanxi Cardiovasc Hosp, Dept Cardiol, Taiyuan, Shanxi, Peoples R China
21.Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430072, Hubei, Peoples R China
22.Cent S Univ, Xiangya Hosp, Dept Cardiol, Changsha, Hunan, Peoples R China
23.Tianjin Med Univ, Gen Hosp, Dept Cardiol, Tianjin, Peoples R China
24.Ningxia Med Coll, Affiliated Hosp, Dept Cardiol, Ningxia, Yinchuan, Peoples R China
25.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100034, Peoples R China
26.Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200433, Peoples R China
推荐引用方式
GB/T 7714
Zheng, Bo,Jiang, Jie,Liu, Huiliang,et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial[J]. EUROPEAN HEART JOURNAL SUPPLEMENTS,2015,17(B):B47-B56.
APA Zheng, Bo.,Jiang, Jie.,Liu, Huiliang.,Zhang, Jun.,Li, Hui.,...&Huo, Yong.(2015).Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial.EUROPEAN HEART JOURNAL SUPPLEMENTS,17(B),B47-B56.
MLA Zheng, Bo,et al."Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial".EUROPEAN HEART JOURNAL SUPPLEMENTS 17.B(2015):B47-B56.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Efficacy and safety (378KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zheng, Bo]的文章
[Jiang, Jie]的文章
[Liu, Huiliang]的文章
百度学术
百度学术中相似的文章
[Zheng, Bo]的文章
[Jiang, Jie]的文章
[Liu, Huiliang]的文章
必应学术
必应学术中相似的文章
[Zheng, Bo]的文章
[Jiang, Jie]的文章
[Liu, Huiliang]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention_results of the ISCAP randomized controlled trial.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。